Research Progress of Cutaneous Squamous and Basal Cell Carcinomas

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue, which aims to explore the relationship between the TIME(tumor immune microenvironment) and the development, progression and treatment of cuSCC.

More than a million new cases of cutaneous squamous cell carcinomas (cuSCC) are diagnosed yearly in the USA, and their incidence is expected to increase worldwide as the population increases in age. As opposed to other nonmelanoma skin cancers, cuSCC are associated with an increased rate of distant metastasis and elevated morbimortality.

Immunosuppression is directly related to the risk of cuSCC development, and chronically immunosuppressed individuals, such as organ transplant recipients and those with hematological malignancies, represent a significant chunk of cuSCC patients. Unfortunately, since immunodeficiency is a major risk factor for metastatic dissemination, these vulnerable patients are more prone to develop advanced disease.

Chronic ultraviolet exposure (UV) is a major etiological factor for cuSCC and promotes a unique mutation signature in these tumors. It is also an important immunosuppressive agent and may contribute to a reduction in the local immunosurveillance, favoring pro-tumorigenic changes such as skin infection by beta human papillomavirus (HPV), which is considered an important promoter of skin carcinogenesis.

Although the relevance of the tumor immune microenvironment (TIME) in the initiation and progression of cuSCC is widely accepted, our understanding of the intricated relationship between the TIME and the cuSCC is limited. Consequently, development and application of new measures for prevention and treatment of cuSCC, especially those linked to immunomodulation, require further exploration.

Original research articles and reviews are welcome. We look forward to receiving your contributions.

Dr. Frederico O. Gleber-Netto
Dr. Moran Amit
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.